Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study

Clinical Colorectal Cancer

Volumn 17, Issue 1, 2018, Pages e59-e68

  Antonio, Maite ^a   Carmona Bayonas, Alberto ^b   Saldaña, Juana ^a   Navarro, Valentí ^c   Tebé, Cristian ^d   Salazar, Ramon ^a   Borràs, Josep Maria ^d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Adherence; Adjuvant therapy; Colorectal cancer; Comprehensive geriatric assessment; Elderly

Indexed keywords

CAPECITABINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; AGED; ANEMIA; ANOREXIA; ARTICLE; BARTHEL INDEX; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG SAFETY; FATIGUE; FEMALE; FRAILTY; FUNCTIONAL STATUS ASSESSMENT; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; OUTCOME VARIABLE; PATIENT COMPLIANCE; POLYPHARMACY; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT REFUSAL; WEAKNESS; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES;

EID: 85031705012     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2017.09.003     Document Type: Article

References (58)

1. Finkel, T., Serrano, M., Blasco, M.A., The common biology of cancer and ageing. Nature 448 (2007), 767–774.
2. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
3. Yang, D.X., Gross, C.P., Soulos, P.R., Yu, J.B., Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer 120 (2014), 2893–2901.
4. André, T., Boni, C., Navarro, M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27 (2009), 3109–3116.
5. Schmoll, H.J., Cartwright, T., Tabernero, J., et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 25 (2007), 102–109.
6. Haller, D.G., Tabernero, J., Maroun, J., et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29 (2011), 1465–1471.
7. Goldberg, R.M., Tabah-Fisch, I., Bleiberg, H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006), 4085–4091.
8. McCleary, N.J., Meyerhardt, J.A., Green, E., et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 31 (2013), 2600–2606.
9. Tournigand, C., André, T., Bonnetain, F., et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30 (2012), 3353–3360.
10. Yothers, G., O'Connell, M.J., Allegra, C.J., et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29 (2011), 3768–3774.
11. Kim, C.A., Spratlin, J.L., Armstrong, D.E., Ghosh, S., Mulder, K.E., Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian Cancer Institute experience. Clin Colorectal Cancer 13 (2014), 199–206.
12. Sanoff, H.K., Carpenter, W.R., Stürmer, T., et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 30 (2012), 2624–2634.
13. McCleary, N.J., Odejide, O., Szymonifka, J., Ryan, D., Hezel, A., Meyerhardt, J.A., Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer. Clin Colorectal Cancer 12 (2013), 62–69.
14. Papamichael, D., Audisio, R.A., Glimelius, B., et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol 26 (2015), 463–476.
15. Twelves, C., Scheithauer, W., McKendrick, J., et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 23 (2012), 1190–1197.
16. Dobie, S.A., Baldwin, L.M., Dominitz, J.A., Matthews, B., Billingsley, K., Barlow, W., Completion of therapy by medicare patients with stage III colon cancer. J Natl Cancer Inst 98 (2006), 610–619.
17. Aspinall, S.L., Good, C.B., Zhao, X., et al. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer 15 (2015), 1–13.
18. Borras, J., Sanchez-Hernandez, A., Navarro, M., et al. Compliance, satisfaction and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. BMJ 322 (2001), 1–5.
19. Font, R., Espinas, J., Layos, L., et al. Adherence to oral capecitabine in preoperative stage II and III rectal cancer patients: do we need to worry?. Ann Oncol 28 (2017), 831–835.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon cancer. Version 2.2015, Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp, Accessed: January 17, 2017.
21. Balducci, L., Management of cancer in the older person: a practical approach. Oncologist 5 (2000), 224–237.
22. Extermann, M., Hurria, A., Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 (2007), 1824–1831.
23. Labianca, R., Nordlinger, B., Beretta, G.D., et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:suppl 6 (2013), vi64–vi72.
24. O'Connor, E.S., Greenblatt, D.Y., LoConte, N.K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29 (2011), 3381–3388.
25. Mahoney, F.I., Barthel, D.W., Functional evaluation: the Barthel Index. Md State Med J 14 (1965), 61–65.
26. Lawton, M.P., Brody, E.M., Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969), 179–186.
27. Pfeiffer, E., A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23 (1975), 433–441.
28. D'Ath, P., Katona, P., Mullan, E., Evans, S., Katona, C., Screening, detection and management of depression in elderly primary care attenders. I: the acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract 11 (1994), 260–266.
29. Saliba, D., Elliott, M., Rubenstein, L.Z., et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49 (2001), 1691–1699.
30. Balducci, L., Beghe, C., The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 35 (2000), 147–154.
31. Trotti, A., Colevas, A.D., Setser, A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003), 176–181.
32. Sargent, D.J., Goldberg, R.M., Jacobson, S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345 (2001), 1091–1097.
33. Hung, A., Mullins, C.D., Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 18 (2013), 54–63.
34. Sabate, E., on behalf of the WHO. Adherence to Long-Term therapies; Evidence for Action. 2003, World Health Organization, Geneva.
35. Wedding, U., Honecker, F., Bokemeyer, C., Pientka, L., Höffken, K., Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14 (2007), 44–56.
36. Kalsi, T., Babic-Illman, G., Ross, P.J., et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer 112 (2015), 1435–1444.
37. Elkin, E.B., Kim, S.H., Casper, E.S., Kissane, D.W., Schrag, D., Desire for information and involvement in treatment decisions: elderly cancer patients’ preferences and their physicians’ perceptions. J Clin Oncol 25 (2007), 5275–5280.
38. Puts, M.T., Tu, H.A., Tourangeau, A., et al. Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol 25 (2014), 564–577.
39. Aaldriks, A.A., van der Geest, L.G., Giltay, E.J., et al. Frailty and malnutrition predictive of mortality risk in older patients with advanced colorectal cancer receiving chemotherapy. J Geriatr Oncol 4 (2013), 218–226.
40. Puts, M.T., Monette, J., Girre, V., et al. Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 78 (2011), 138–149.
41. Marinello, R., Marenco, D., Roglia, D., et al. Predictors of treatment failures during chemotherapy: a prospective study on 110 older cancer patients. Arch Gerontol Geriatr 48 (2009), 222–226.
42. Hamaker, M.E., Seynaeve, C., Wymenga, A.N., et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists’ group. Breast 23 (2014), 81–87.
43. Versteeg, K.S., Konings, I.R., Lagaay, A.M., van de Loosdrecht, A.A., Verheul, H.M., Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review. Ann Oncol 25 (2014), 1914–1918.
44. Hurria, A., Mohile, S., Gajra, A., et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 34 (2016), 2366–2371.
45. Extermann, M., Boler, I., Reich, R.R., et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 118 (2012), 3377–3386.
46. Hamaker, M.E., Vos, A.G., Smorenburg, C.H., de Rooij, S.E., van Munster, B.C., The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 17 (2012), 1439–1449.
47. Luciani, A., Biganzoli, L., Colloca, G., et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol 6 (2015), 272–279.
48. Van Erning, F.N., Razenberg, L.G., Lemmens, V.E., et al. Intensity of adjuvant chemotherapy regimens and Grade III-V toxicities among elderly stage III colon cancer patients. Eur J Cancer 61 (2016), 1–10.
49. Chang, H.J., Lee, K.W., Kim, J.H., et al. Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. Ann Oncol 23 (2012), 911–918.
50. Font, R., Espinas, J.A., Gil-Gil, M., et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107 (2012), 1249–1256.
51. Wildes, T.M., Ruwe, A.P., Fournier, C., et al. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol 4 (2013), 227–234.
52. Aaldriks, A.A., Maartense, E., le Cessie, S., et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol 79 (2011), 205–212.
53. Laurent, M., Paillaud, E., Tournigand, C., et al. Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study. Oncologist 19 (2014), 275–282.
54. Ho, J., Gill, S., Woods, R., Association of survival outcomes with dose intensity of adjuvant therapy with capecitabine for colorectal cancer. J Clin Oncol, 28(15 suppl), 2010, 3624.
55. Biganzoli, L., Lichtman, S., Michel, J.P., et al. Oral single-agent chemotherapy in older patients with solid tumours: a position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer 51 (2015), 2491–2500.
56. Ahmed, S., Ahmad, I., Zhu, T., et al. Early discontinuation but not the timing of adjuvant therapy affects survival of patients with high-risk colorectal cancer: a population-based study. Dis Colon Rectum 53 (2010), 1432–1438.
57. Antonio, M., Saldaña, J., Carmona-Bayonas, A., Geriatric assessment predicts survival and competing mortality in elderly patients with early colorectal cancer. Can it help in adjuvant therapy decision-making?. Oncologist 22 (2017), 934–943.
58. Verweij, N.M., Schiphorst, A.H., Pronk, A., van den Bos, F., Hamaker, M.E., Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol 55 (2016), 1386–1391.